Three years after completing the vaccine series, 93% of high-risk melanoma patients remained alive, while 77% of patients who were given placebos survived, according to final data from a prospective, randomized, double-blind, placebo-controlled phase IIb clinical trial.

Elios' personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made from a patient's tumor and blood. Every patient's tumor has a unique antigenic profile unlike any other, and dendritic cells found in the blood are the most potent antigen-presenting cells in the body.

Enterome begins trial for microbiome-based immunotherapy
Clinical-stage biopharmaceutical company Enterome has begun its first clinical trial for E02401, a microbiome-based cancer immunotherapy candidate.

Researchers discuss progress toward personalized cancer vaccines
Highly targeted and adaptable platforms allow researchers to develop cancer vaccines for a multitude of different cancer types and even create personalized...